Clinical Trials · NCT05035082
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,020
- Start date
- Sep 2021
- Locations
- 25 sites, United States
- Primary endpoint
- Change in Glycosylated hemoglobin A1c (HbA1c)